MarketPeel
Insider Trading Intelligence
Pricing
…
DL

David Lebwohl

NTLA
EVP, CHIEF MEDICAL OFFICER · INTELLIA THERAPEUTICS, INC. · CIK 0001810882
FILING MIX · LIFETIME44%/56%
BUYS
24
SELLS
31
TOTAL VALUE
$2.62M
COMPANIES
1
ACTIVE SINCE
May 2020
HOLDINGS NOW
14,204
AVG SELL PX
$55.24
TRADE KIND
SHOWING 55 / 55
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
21 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by David Lebwohl, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d21+47.62%+0.42%+0.66%-0.24%-0.66%—
14d21+47.62%-1.98%+0.62%-2.60%-0.28%—
30d21+66.67%-8.41%+0.79%-9.20%-7.02%—
60d21+85.71%-11.16%+2.63%-13.79%-18.48%—
90d21+95.24%-22.75%+2.10%-24.85%-30.49%—
180d21+90.48%-37.27%-0.62%-36.65%-42.30%—
1y21(1 pending)+100.00%-57.75%-9.34%-48.41%-46.02%—
2y21(2 pending)+100.00%-76.10%+6.12%-82.22%-77.92%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NTLA · 14,204 shares · as of Mar 1, 2026
050,000100,000150,000200,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 24 buys / 31 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,943——131,192Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,204——14,204Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
11,903$9.21$109.6K121,249Jan 5, 2026Jan 7, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
61,714——61,714Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,200——130,866Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
9,557$12.18$116.4K87,666Jan 3, 2025Jan 7, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
3,189——0Jan 1, 2025Jan 3, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
3,189——97,223Jan 1, 2025Jan 3, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,701——93,073Mar 1, 2024Mar 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,855——55,855Mar 1, 2024Mar 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
5,843$29.46$172.1K54,372Jan 3, 2024Jan 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
3,187——3,189Jan 1, 2024Jan 3, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
3,187——60,215Jan 1, 2024Jan 3, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,342——43,342Mar 1, 2023Mar 3, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,674——56,361Mar 1, 2023Mar 3, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,574$37.21$95.8K25,687Jan 4, 2023Jan 6, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
3,187——28,261Jan 1, 2023Jan 4, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
3,187——6,376Jan 1, 2023Jan 4, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,203——20,203Mar 1, 2022Mar 4, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,816——24,738Mar 1, 2022Mar 3, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,816——13,816Mar 1, 2022Mar 3, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
1,051$112.24$118.0K10,922Jan 1, 2022Mar 3, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
3,187——9,563Jan 1, 2022Mar 3, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
3,187——11,973Jan 1, 2022Mar 3, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400——180,077Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
200$135.34$27.1K8,714Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
2,400$12.62$30.3K11,114Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
452$132.62$59.9K9,462Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
1,200$131.71$158.1K9,914Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
548$134.07$73.5K8,914Nov 5, 2021Nov 9, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
525$129.83$68.2K8,964Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
250$130.47$32.6K8,714Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
551$126.92$69.9K10,563Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
2,400$12.62$30.3K11,114Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
225$129.01$29.0K9,489Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
849$127.81$108.5K9,714Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400——182,477Oct 14, 2021Oct 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
7,923——184,877Sep 24, 2021Sep 27, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
7,923$12.62$100.0K8,714Sep 24, 2021Sep 27, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400$149.81$359.5K791Sep 21, 2021Sep 23, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
2,400$12.62$30.3K3,191Sep 21, 2021Sep 23, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400——192,800Sep 21, 2021Sep 23, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
200$155.43$31.1K2,991Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
250$157.60$39.4K2,041Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400——195,200Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
1,100$159.19$175.1K941Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
150$160.10$24.0K791Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
2,400$12.62$30.3K3,191Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
700$156.70$109.7K2,291Aug 30, 2021Sep 1, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Medical Officer
2,400$12.62$30.3K3,191Aug 9, 2021Aug 11, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400——197,600Aug 9, 2021Aug 11, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Medical Officer
2,400$164.05$393.7K791Aug 9, 2021Aug 11, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
76,500——76,500Mar 3, 2021Mar 5, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,750——12,750Mar 3, 2021Mar 5, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000——200,000May 1, 2020May 5, 2020 ↗View →
Other insiders · NTLA
Loading peer insiders…
About this filer
CIK 0001810882
ROLE
EVP, Chief Medical Officer
PRIMARY
NTLA
COMPANIES
1
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001810882DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback